- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00810953
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
June 27, 2011 updated by: Oncozyme Pharma Inc.
A Phase I/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.
Study Overview
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically proven diagnosis of advanced pancreatic adenocarcinoma that is unresectable or metastatic. At least one uni-dimensionally measurable lesion (on spiral CT scan)
- 18 years of age or older
- ECOG performance status 0, 1 or 2
- Serum aspartate transaminase (AST) serum alanine transaminase (ALT) £ 2.5 x upper limit of normal (ULN), or AST and ALT £ 5 x ULN if liver function abnormalities are due to underlying malignancy
- Total serum bilirubin £ 2 x ULN
- lipase within normal limits (1.5x ULN)
- Absolute neutrophil count (ANC) ≥ 1500/uL (1.5 x 109/L)
- Platelets ≥ 100,000/uL
- Hemoglobin ≥ 9.0 g/dL
- Serum creatinine £ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min
- CA19-9 level ≥ 37 U/ml
- Normal ECG
- Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures
- Life expectancy, in the opinion of the investigator, > 3 months
Exclusion Criteria:
- BP < 100 (systolic)
- History of uncontrolled renal disease, pancreatitis, or diabetes mellitus
- Peripheral sensory neuropathy (> Grade 1, as per NCI CTCAE version 3.0)
- Concomitant therapy with other investigational agents or participation in another clinical trial within the previous 3 months.
- Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2; atrial fibrillation of any grade; QTc interval >450 msec for males or >470 msec for females or uncontrolled intercurrent illness, e.g., unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia <50 bpm
- Active uncontrolled bacterial infection
- Concurrent use of drugs that could prolong QT interval
- Concurrent use of nephrotoxic drugs, including aminoglycosides, ampho B, foscarnet, cidofovir
- Concurrent use of drugs that may be associated with pancreatitis
- Concurrent active cancer originating from a primary site other than pancreas or history of cancer < 3 years except for skin superficial bladder, uterus etc
- History of allergy or hypersensitivity to pentamidine
- Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to first dose of study medication.
- Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgement of the investigator, excess risk associated with trial participation of study drug administration, or which in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
- On oral anticoagulants (LMWH is acceptable)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
Use of pentamidine in locally advanced or metastatic pancreatic cancer
|
two dose of 6 mg/kg with or without standard chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Any severe events, tumor marker CA19-9, and tumor size (CT scan)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
TDP
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Petr Kavan, MD, Ph.D., McGill University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
December 16, 2008
First Submitted That Met QC Criteria
December 17, 2008
First Posted (Estimate)
December 18, 2008
Study Record Updates
Last Update Posted (Estimate)
June 28, 2011
Last Update Submitted That Met QC Criteria
June 27, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OP-103-P
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on Pentamidine
-
Fundação de Medicina Tropical Dr. Heitor Vieira...Completed
-
FisonsCompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
Mayo ClinicTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
FisonsCompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
FisonsCompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
FisonsCompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)TerminatedMelanoma (Skin)United States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Pneumonia, Pneumocystis CariniiUnited States